≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Ectopic testis

Endpoint Browser PheWeb

Q17_ECTOPIC_TESTIS

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — Q55.20
  • Cause of death: ICD-10 — Q55.20

2 out of 7 registries used, show all original rules.

195

4. Check minimum number of events

None

195

5. Include endpoints

None

195

6. Filter based on genotype QC (FinnGen only)

171

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded (different definition than used in FinnGen).

-FinnGen-

Key figures

All Female Male
Number of individuals 171 - 170
Unadjusted period prevalence (%) 0.08 - 0.08
Median age at first event (years) 7.78 - 7.77

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
195
Matched controls
1950
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
Q55.20
ICD-10 Finland
Retractile testis
+∞
274.5
195
*
Q53.1
ICD-10 Finland
Undescended testicle, unilateral
26.3
61.0
45
22
KFH00
NOMESCO Finland
Operation for undescended or ectopic testis
27.9
58.6
42
19
KFH10
NOMESCO Finland
Orchiopexy
18.4
19.5
30
19
KF8AE
NOMESCO Finland
Ultrasound examination of scrotum
3.6
6.8
24
74
Q53.9
ICD-10 Finland
Undescended testicle, unspecified
41.5
6.8
8
*
G03GA01
ATC
chorionic gonadotrophin; parenteral
27.7
6.3
8
*

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Outpatient Visit
OP [9202]
-3.3e-01
-9.7e-02
-6.0e-02
5.4e+00
1.1e+00
4.1e-02
-7.7e-02
cases:62.20%
controls:69.63%
cases:53.19%
controls:55.60%
cases:14.18%
controls:14.93%
cases:49.65%
controls:0.45%
cases:35.46%
controls:15.82%
cases:53.90%
controls:52.88%
cases:72.59%
controls:74.09%
79
853
48
372
75
745
66
595
20
200
121
1140
70
6
71
1334
50
212
91
1128
76
707
65
630
98
941
37
329
Pediatric Surgery
OMOP4822020 [45756819]
3.2e-01
5.6e-01
—
—
3.2e+00
1.3e+00
9.8e-01
cases:18.90%
controls:14.53%
cases:11.35%
controls:6.79%
—
—
—
—
cases:21.99%
controls:1.12%
cases:17.02%
controls:5.31%
cases:31.11%
controls:14.49%
24
178
103
1047
16
91
125
1249
—
—
31
15
110
1325
24
71
117
1266
42
184
93
1086
Undescended testicle, unilateral
Q53.1 [45597134]
—
—
—
—
—
2.1e+00
2.8e+00
—
—
—
—
—
—
—
—
—
—
cases:3.55%
controls:0.45%
cases:9.63%
controls:0.63%
—
—
—
—
—
5
6
136
1331
13
8
122
1262
Urology
34 [38004474]
—
—
—
1.0e+50
—
2.7e+00
1.0e+00
—
—
—
—
—
—
cases:12.06%
controls:0.00%
—
—
cases:7.09%
controls:0.52%
cases:5.19%
controls:1.97%
—
—
—
17
0
124
1340
—
10
7
131
1330
7
25
128
1245
Case Management Agency
251B00000X [38004193]
-2.0e-01
9.8e-02
-3.8e-01
2.6e+00
3.7e-01
-6.4e-03
2.8e-02
cases:42.52%
controls:47.51%
cases:43.97%
controls:41.57%
cases:14.18%
controls:19.48%
cases:14.18%
controls:1.19%
cases:23.40%
controls:17.46%
cases:43.97%
controls:44.13%
cases:59.26%
controls:58.58%
54
582
73
643
62
557
79
783
20
261
121
1079
20
16
121
1324
33
234
108
1106
62
590
79
747
80
744
55
526
Urinary tract ultrasound examination
KH1AE [2001306329]
1.9e+00
—
—
—
—
—
—
cases:5.51%
controls:0.90%
—
—
—
—
—
—
—
—
—
—
—
—
7
11
120
1214
—
—
—
—
—
—
Scheduled procedure
ZXD10 [2001311387]
-3.6e-01
—
-1.0e+50
—
—
7.9e-01
1.7e+00
cases:8.66%
controls:12.00%
—
—
cases:0.00%
controls:0.52%
—
—
—
—
cases:3.55%
controls:1.65%
cases:8.89%
controls:1.81%
11
147
116
1078
—
0
7
141
1333
—
—
5
22
136
1315
12
23
123
1247
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
R5110 [2001310246]
1.6e+00
—
—
—
—
—
1.2e+00
cases:7.09%
controls:1.47%
—
—
—
—
—
—
—
—
—
—
cases:5.19%
controls:1.65%
9
18
118
1207
—
—
—
—
—
7
21
128
1249
General Surgery
2 [38004447]
1.5e-01
8.9e-01
—
1.0e+50
—
1.4e+00
3.1e-01
cases:11.02%
controls:9.63%
cases:4.96%
controls:2.09%
—
—
cases:15.60%
controls:0.00%
—
—
cases:7.80%
controls:2.02%
cases:11.85%
controls:8.98%
14
118
113
1107
7
28
134
1312
—
22
0
119
1340
—
11
27
130
1310
16
114
119
1156
Supplier / Service Provider
OMOP5117446 [33004]
-1.1e+00
-1.2e+00
—
—
—
—
2.0e+00
cases:8.66%
controls:21.96%
cases:3.55%
controls:11.34%
—
—
—
—
—
—
—
—
cases:14.81%
controls:2.28%
11
269
116
956
5
152
136
1188
—
—
—
—
20
29
115
1241
Asthma
R96 [2002000961]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
0
7
135
1263
IgE [Units/volume] in Serum or Plasma
19113-0 [3005322]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.42%
—
—
—
—
—
—
0
18
135
1252
Congenital stenosis of aortic valve
Q23.0 [45587449]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.41%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
cases:0.00%
controls:0.37%
cases:0.00%
controls:0.63%
0
5
127
1220
0
6
141
1334
—
—
—
0
5
141
1332
0
8
135
1262
nedocromil; inhalant
R03BC03 [21603299]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
127
1217
—
—
—
—
—
—
Contusion of elbow
S50.0 [45597855]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
5
135
1265
Psychiatric/psychological examination
SPAT1243 [2001700344]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.10%
—
—
—
—
—
—
0
14
135
1256
Specialty-specific consultation based on referral by dentist or doctor
WZC05 [2001310886]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
0
9
127
1216
—
—
—
—
0
5
141
1332
—
olopatadine
S01GX09 [21605093]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
5
135
1265
PEF monitoring instruction
SPAT1058 [2001700159]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
0
6
135
1264
chloramphenicol
S03AA08 [21605197]
-3.2e-01
—
-1.0e+50
—
-1.0e+50
9.0e-03
-4.9e-02
cases:7.87%
controls:10.53%
—
—
cases:0.00%
controls:0.37%
—
—
cases:0.00%
controls:0.67%
cases:3.55%
controls:3.52%
cases:8.89%
controls:9.29%
10
129
117
1096
—
0
5
141
1335
—
0
9
141
1331
5
47
136
1290
12
118
123
1152
Exposure to unspecified factor
X59 [45756412]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.31%
—
—
—
—
—
—
—
—
—
—
—
—
0
16
127
1209
—
—
—
—
—
—
Ovomucoid IgE Ab [Units/volume] in Serum
7557-2 [3003633]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
0
5
141
1335
—
—
—
—
—
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
7.9e-01
—
—
—
—
-1.0e+50
—
cases:4.72%
controls:2.20%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
6
27
121
1198
—
—
—
—
0
8
141
1329
—
Altered pattern of family relationships in childhood
Z61.2 [45600339]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
127
1220
—
—
—
—
—
—
Strabismus, unspecified
H50.9 [45581701]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
0
6
127
1219
—
—
—
—
—
0
6
135
1264
Risk factor NOS
A23 [2002000158]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
0
6
141
1331
—
propranolol; oral, parenteral
C07AA05 [21601670]
—
—
—
—
—
1.9e+00
1.7e+00
—
—
—
—
—
—
—
—
—
—
cases:3.55%
controls:0.52%
cases:4.44%
controls:0.87%
—
—
—
—
—
5
7
136
1330
6
11
129
1259
omeprazole; oral, parenteral
A02BC01 [21600096]
3.0e-01
—
-1.0e+50
—
—
—
—
cases:3.94%
controls:2.94%
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
5
36
122
1189
—
0
6
141
1334
—
—
—
—
Gas panel - Capillary blood
24337-8 [3022313]
1.8e-01
7.4e-02
—
—
—
—
1.0e+00
cases:7.87%
controls:6.69%
cases:4.96%
controls:4.63%
—
—
—
—
—
—
—
—
cases:7.41%
controls:2.83%
10
82
117
1143
7
62
134
1278
—
—
—
—
10
36
125
1234
Impetigo
L01 [45548179]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
5
135
1265
Short stature, not elsewhere classified
E34.39 [2000501487]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.73%
cases:0.00%
controls:0.67%
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
0
9
127
1216
0
9
141
1331
—
—
—
0
6
141
1331
—
Meeting with student welfare group of educational institution
SPAT1369 [2001700470]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
127
1220
—
—
—
—
—
—
Hypertrophy of adenoids
J35.2 [45552887]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
—
0
10
141
1330
—
—
—
—
—
Urea [Moles/volume] in Serum or Plasma
22664-7 [3020779]
2.5e-01
1.2e-01
—
—
—
7.8e-01
5.2e-01
cases:5.51%
controls:4.33%
cases:4.26%
controls:3.81%
—
—
—
—
—
—
cases:5.67%
controls:2.69%
cases:5.93%
controls:3.62%
7
53
120
1172
6
51
135
1289
—
—
—
8
36
133
1301
8
46
127
1224
Rotaviral enteritis
A08.0 [45605188]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
127
1220
—
—
—
—
—
—
Neonatal screening
60151004 [4246502]
4.5e-01
—
—
—
—
—
—
cases:7.09%
controls:4.65%
—
—
—
—
—
—
—
—
—
—
—
—
9
57
118
1168
—
—
—
—
—
—
Chemotherapy session for neoplasm
Z51.1 [45595526]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
127
1219
—
—
—
—
—
—
Check up of cardiac pacemaker
XFP20 [2001303367]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
127
1220
—
—
—
—
—
—
Other specified disorders involving the immune mechanism, not elsewhere classified
D89.89 [2000501403]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
cases:0.00%
controls:0.67%
cases:0.00%
controls:0.87%
—
0
7
141
1333
—
—
—
0
9
141
1328
0
11
135
1259
levofloxacin
S01AE05 [43534860]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
127
1220
—
—
—
—
—
—
Extended examination of mouth
SAA03 [2001310276]
-3.2e-01
1.5e-01
-1.0e+50
—
-1.0e+50
3.5e-02
8.0e-02
cases:8.66%
controls:11.59%
cases:7.09%
controls:6.19%
cases:0.00%
controls:0.82%
—
—
cases:0.00%
controls:0.60%
cases:7.80%
controls:7.55%
cases:22.22%
controls:20.87%
11
142
116
1083
10
83
131
1257
0
11
141
1329
—
0
8
141
1332
11
101
130
1236
30
265
105
1005
Herpes virus 6 DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
33942-4 [3046896]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
127
1216
—
—
—
—
—
—
budesonide; oral, sublingual
A07EA06 [21600658]
—
-1.0e+50
—
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
0
8
141
1332
—
—
0
5
141
1335
—
—
combinations of corticosteroids
D07AB30 [21602118]
3.3e-01
—
—
—
—
—
-7.7e-01
cases:13.39%
controls:9.96%
—
—
—
—
—
—
—
—
—
—
cases:3.70%
controls:7.64%
17
122
110
1103
—
—
—
—
—
5
97
130
1173
Leukocytes [#/volume] in Urine
30405-5 [3018095]
-2.3e-03
1.6e-01
—
—
—
7.2e-01
1.7e-01
cases:7.09%
controls:7.10%
cases:4.96%
controls:4.25%
—
—
—
—
—
—
cases:6.38%
controls:3.22%
cases:8.89%
controls:7.64%
9
87
118
1138
7
57
134
1283
—
—
—
9
43
132
1294
12
97
123
1173
Catheterisation of heart with other procedure
TFC99 [2001303401]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
127
1216
—
—
—
—
—
—
Retractile testis
Q55.20 [2000503398]
—
1.0e+50
—
1.0e+50
1.0e+50
1.0e+50
1.0e+50
—
—
cases:5.67%
controls:0.00%
—
—
cases:70.92%
controls:0.00%
cases:31.21%
controls:0.00%
cases:21.28%
controls:0.00%
cases:22.22%
controls:0.00%
—
8
0
133
1340
—
100
0
41
1340
44
0
97
1340
30
0
111
1337
30
0
105
1270
Assessment of need for rehabilitation and/or rehabilitation plan
SPAT1220 [2001700321]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.10%
—
—
—
—
—
—
0
14
135
1256
naproxcinod
M01AE18 [40254094]
1.3e-01
1.2e-01
—
—
—
4.4e-01
-6.0e-02
cases:20.47%
controls:18.45%
cases:5.67%
controls:5.07%
—
—
—
—
—
—
cases:5.67%
controls:3.74%
cases:10.37%
controls:10.94%
26
226
101
999
8
68
133
1272
—
—
—
8
50
133
1287
14
139
121
1131
Paediatric neurology
421 [44777781]
-4.7e-03
3.3e-01
—
—
—
3.9e-01
3.8e-01
cases:14.96%
controls:15.02%
cases:12.77%
controls:9.55%
—
—
—
—
—
—
cases:13.48%
controls:9.57%
cases:17.04%
controls:12.36%
19
184
108
1041
18
128
123
1212
—
—
—
19
128
122
1209
23
157
112
1113
Seborrhoeic keratosis
L82 [45548208]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
127
1220
—
—
—
—
—
—
Prenatal enamel hypoplasia
K00.41 [2000502633]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
127
1217
—
—
—
—
—
—
Skin injury other
S19 [2002000984]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
127
1219
—
—
—
—
—
—
Fracture of rib
S22.3 [45573285]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
0
6
135
1264
Acute upper respiratory infection, unspecified
J06.9 [45562437]
4.1e-01
—
—
—
—
3.0e-02
-3.2e-01
cases:20.47%
controls:14.53%
—
—
—
—
—
—
—
—
cases:6.38%
controls:6.21%
cases:11.85%
controls:15.59%
26
178
101
1047
—
—
—
—
9
83
132
1254
16
198
119
1072
Milk IgE Ab [Units/volume] in Serum
6174-7 [3020874]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.97%
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
0
13
141
1327
—
—
—
0
8
141
1329
—
Assessment of need for aid
SPAT1229 [2001700330]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
0
6
135
1264
quetiapine; oral
N05AH04 [21604544]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
0
6
141
1334
—
—
—
—
fusidic acid; ointment
D06AX01 [21602062]
-2.3e-03
-1.0e+50
—
—
—
-1.0e+50
—
cases:4.72%
controls:4.73%
cases:0.00%
controls:1.34%
—
—
—
—
—
—
cases:0.00%
controls:1.35%
—
—
6
58
121
1167
0
18
141
1322
—
—
—
0
18
141
1319
—
Cerebrospinal fluid IgG ratio and IgG index
1324000 [4027681]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
127
1218
—
—
—
—
—
—
Lutropin [Units/volume] in Serum or Plasma
10501-5 [3009214]
—
—
—
—
—
—
2.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.70%
controls:2.99%
—
—
—
—
—
—
5
38
130
1232
Viral infection, unspecified
B34.9 [45605229]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
0
11
141
1329
—
—
—
—
—
betamethasone
A07EA04 [21600656]
—
-1.0e+50
—
—
—
—
7.6e-01
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
cases:4.44%
controls:2.13%
—
0
8
141
1332
—
—
—
—
6
27
129
1243
Acute bronchitis
J20 [45581849]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
0
12
135
1258
ezetimibe; oral
C10AX09 [21601896]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
0
5
141
1335
—
—
—
0
6
141
1331
—
fluocortolone
C05AA08 [21601612]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
5
135
1265
Separate planning of oral and dental treatment, standard
SAC01 [2001310283]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
cases:0.00%
controls:1.65%
—
—
—
—
—
0
5
141
1332
0
21
135
1249
Dysuria
R30.0 [45592416]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
127
1219
—
—
—
—
—
—
glyceryl trinitrate; local oral, oral, sublingual, transdermal
C01DA02 [21600317]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.14%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
0
14
127
1211
—
—
—
—
0
6
141
1331
—
Place of Employment-Worksite
18 [581475]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
0
8
141
1332
—
—
—
—
—
European house dust mite IgE Ab [Units/volume] in Serum
6096-2 [3023351]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.50%
—
—
—
—
—
—
0
19
135
1251
naproxen; oral, rectal
M01AE02 [21603968]
1.3e-01
1.2e-01
—
—
—
4.4e-01
-6.0e-02
cases:20.47%
controls:18.45%
cases:5.67%
controls:5.07%
—
—
—
—
—
—
cases:5.67%
controls:3.74%
cases:10.37%
controls:10.94%
26
226
101
999
8
68
133
1272
—
—
—
8
50
133
1287
14
139
121
1131
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
1.3e-01
-2.3e-01
—
—
—
5.9e-01
2.5e-01
cases:12.60%
controls:11.27%
cases:4.26%
controls:5.30%
—
—
—
—
—
—
cases:7.80%
controls:4.49%
cases:14.81%
controls:11.89%
16
138
111
1087
6
71
135
1269
—
—
—
11
60
130
1277
20
151
115
1119
Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture
546-2 [3024135]
3.3e-01
6.0e-01
—
—
—
—
-1.7e-01
cases:7.87%
controls:5.80%
cases:4.26%
controls:2.39%
—
—
—
—
—
—
—
—
cases:5.93%
controls:6.93%
10
71
117
1154
6
32
135
1308
—
—
—
—
8
88
127
1182
Retrognaty, mandibular
K07.13 [2000502762]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
0
6
141
1331
—
levocabastine
S01GX02 [21605086]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.39%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
0
17
127
1208
0
6
141
1334
—
—
—
—
0
7
135
1263
Syndrome Beckwith-Wiedemann
Q87.30 [2000503559]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
0
5
141
1332
—
Headache
N01 [2002000720]
—
-1.0e+50
—
—
—
—
-6.3e-02
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
cases:3.70%
controls:3.94%
—
0
5
141
1335
—
—
—
—
5
50
130
1220
Chronic hypertension
205 [2001600203]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
0
10
127
1215
—
—
—
—
—
0
7
135
1263
Ova and parasites identified in Stool by Light microscopy
10704-5 [3003327]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.26%
—
0
9
141
1331
—
—
—
—
0
16
135
1254
Extensive health check-up on eighth grade
SPAT1386 [2001700486]
—
-1.0e+50
—
—
—
-1.0e+50
-2.4e-03
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
cases:0.00%
controls:0.45%
cases:5.19%
controls:5.20%
—
0
5
141
1335
—
—
—
0
6
141
1331
7
66
128
1204
Malaise and fatigue
R53 [45553741]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
0
11
141
1329
—
—
—
—
—
Cytomegalovirus IgG Ab [Units/volume] in Serum or Plasma
7852-7 [3010130]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
0
5
141
1332
—
General Practice Dentistry
1223G0001X [38003675]
—
—
—
—
-1.0e+50
—
-7.2e-01
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
cases:3.70%
controls:7.32%
—
—
—
—
0
6
141
1334
—
5
93
130
1177
lidocaine
R02AD02 [21603243]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
127
1219
—
—
—
—
—
—
oxcarbazepine; oral
N03AF02 [21604418]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
0
9
141
1331
—
—
—
0
8
141
1329
—
Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma
1805-1 [3016417]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
0
5
141
1335
—
—
—
—
—
Acute myeloblastic leukaemia [AML]
C92.0 [45600565]
-1.0e+50
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.57%
cases:0.00%
controls:0.75%
cases:0.00%
controls:0.37%
—
—
—
—
cases:0.00%
controls:0.67%
cases:0.00%
controls:0.71%
0
7
127
1218
0
10
141
1330
0
5
141
1335
—
—
0
9
141
1328
0
9
135
1261
Obstetrics / Gynecology
16 [38004461]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
0
7
141
1333
—
—
—
—
—
Assessment of need for oral health care, extensive
SAD02 [2001310288]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
0
10
141
1327
—
Chronic apical periodontitis
K04.5 [45586691]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
127
1216
—
—
—
—
—
—
combinations of corticosteroids
D07XB30 [21602188]
3.3e-01
—
—
—
—
—
-7.7e-01
cases:13.39%
controls:9.96%
—
—
—
—
—
—
—
—
—
—
cases:3.70%
controls:7.64%
17
122
110
1103
—
—
—
—
—
5
97
130
1173
Anomalies of dental arch relationship
K07.22 [2000502768]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
cases:0.00%
controls:1.81%
0
5
127
1220
—
—
—
—
0
6
141
1331
0
23
135
1247
Skin colour change
S08 [2002000973]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
5
135
1265
Sepsis due to Streptococcus pneumoniae
A40.3 [45590813]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
127
1220
—
—
—
—
—
—
Herpes simplex virus 2 IgG Ab [Presence] in Cerebral spinal fluid
27315-1 [3007695]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
127
1220
—
—
—
—
—
—
Influenza virus B Ag [Presence] in Specimen
31864-2 [3003740]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.63%
0
6
127
1219
—
—
—
—
—
0
8
135
1262
sumatriptan; nasal, oral, parenteral, rectal
N02CC01 [21604376]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.02%
—
—
—
—
—
—
0
13
135
1257
Profession-specific psychiatric evaluation
IBZ01 [2001304075]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.44%
controls:1.18%
—
—
—
—
—
—
6
15
129
1255
dexchlorpheniramine, combinations
R06AB52 [21603467]
5.8e-01
—
—
—
—
—
—
cases:4.72%
controls:2.69%
—
—
—
—
—
—
—
—
—
—
—
—
6
33
121
1192
—
—
—
—
—
—
filgrastim; parenteral
L03AA02 [21603851]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
127
1220
—
—
—
—
—
—
zoster, live attenuated
J07BK02 [21601363]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:2.12%
—
—
—
—
—
—
—
—
—
—
—
—
0
26
127
1199
—
—
—
—
—
—
Sickle-cell anaemia without crisis
D57.1 [45542709]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
0
5
141
1335
—
—
—
—
—
Elbow symptom/complaint
L10 [2002000634]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
5
135
1265
Bacteria identified in Blood by Culture
600-7 [3023368]
6.4e-01
—
—
—
—
—
—
cases:3.94%
controls:2.12%
—
—
—
—
—
—
—
—
—
—
—
—
5
26
122
1199
—
—
—
—
—
—
Skin texture symptom/complaint
S21 [2002000986]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.90%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
127
1214
—
—
—
—
—
—
Disturbance of activity and attention
F90.0 [45542870]
—
—
-1.0e+50
—
—
—
1.5e-01
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
cases:4.44%
controls:3.86%
—
—
0
6
141
1334
—
—
—
6
49
129
1221
desonide
D07AB08 [21602112]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.90%
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
0
12
141
1328
—
—
—
0
8
141
1329
—
Convergent concomitant strabismus
H50.0 [45552716]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
127
1217
—
—
—
—
—
—
Special examination of mouth
SAA04 [2001310277]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
0
9
141
1331
—
—
—
0
5
141
1332
—
Wheat IgE Ab [Units/volume] in Serum
6276-0 [3027231]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.97%
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
0
13
141
1327
—
—
—
0
6
141
1331
—
Type 1 diabetes mellitus, With multiple complications
E10.7 [45571655]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
0
7
135
1263
Migraine with aura [classical migraine]
G43.1 [45562086]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
0
6
135
1264
Orthodontic treatment/control appointment
SJX20 [2001310454]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
cases:0.00%
controls:1.42%
—
—
—
—
—
0
8
141
1329
0
18
135
1252
Contusion of thorax
S20.2 [45597402]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
5
135
1265
Carbon dioxide [Partial pressure] in Capillary blood
2020-6 [3023024]
7.5e-02
-9.8e-02
—
—
—
2.0e-01
6.7e-01
cases:7.87%
controls:7.35%
cases:4.96%
controls:5.45%
—
—
—
—
—
—
cases:3.55%
controls:2.92%
cases:8.15%
controls:4.33%
10
90
117
1135
7
73
134
1267
—
—
—
5
39
136
1298
11
55
124
1215
Inpatient Visit
IP [9201]
8.1e-01
—
—
—
—
—
7.9e-01
cases:3.94%
controls:1.80%
—
—
—
—
—
—
—
—
—
—
cases:8.15%
controls:3.86%
5
22
122
1203
—
—
—
—
—
11
49
124
1221
Adenovirus Ag [Presence] in Stool
31711-5 [3020393]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
0
8
135
1262
Isolated deficiency of growth hormone
E23.01 [2000501469]
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.41%
cases:0.00%
controls:0.90%
—
—
—
—
cases:0.00%
controls:0.37%
cases:0.00%
controls:1.12%
cases:0.00%
controls:1.97%
0
5
127
1220
0
12
141
1328
—
—
0
5
141
1335
0
15
141
1322
0
25
135
1245
Transferrin receptor.soluble [Mass/volume] in Serum or Plasma
30248-9 [3015399]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
0
5
141
1335
—
—
—
—
Examination for driving licence
Z02.4 [45552056]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
127
1220
—
—
—
—
—
—
Norovirus RNA [Presence] in Stool by NAA with probe detection
7974-9 [3008909]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
—
—
—
—
—
—
0
11
135
1259
Other and unspecified skin changes
R23.8 [45573020]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.94%
—
—
—
—
—
—
0
12
135
1258
FVC percent change Respiratory system
69982-7 [42868471]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
cases:0.00%
controls:1.05%
—
—
—
0
9
141
1331
—
—
—
0
14
141
1323
—
xylometazoline; nasal
R01AA07 [21605016]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
cases:0.00%
controls:0.52%
cases:0.00%
controls:1.65%
—
0
14
141
1326
—
—
—
0
7
141
1330
0
21
135
1249
candesartan; oral
C09CA06 [21601829]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
127
1220
—
—
—
—
—
—
Acute appendicitis, unspecified
K35.9 [45557651]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
0
9
135
1261
Gliadin peptide IgG Ab [Units/volume] in Serum by Immunoassay
63459-2 [40766189]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
127
1219
—
—
—
—
—
—
Erosion of teeth due to: diet
K03.22 [2000502677]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
0
8
135
1262
Standard cardiac ultrasound examination
FM1AE [2001303278]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.80%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.02%
0
22
127
1203
—
—
—
—
—
0
13
135
1257
Person encountering health services in unspecified circumstances
Z76.9 [45609967]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.65%
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.63%
0
8
127
1217
0
5
141
1335
—
—
—
—
0
8
135
1262
Procedure duration 120 to 149 minutes
ZXE15 [2001311406]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
0
5
141
1335
—
—
—
—
—
Allergic and dietetic gastroenteritis and colitis
K52.2 [45591595]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.80%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
cases:0.00%
controls:0.79%
0
22
127
1203
—
—
—
—
0
9
141
1328
0
10
135
1260
valaciclovir; oral
J05AB11 [21603137]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
0
8
135
1262
Albumin [Mass/volume] in Urine
1754-1 [3012516]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.05%
—
—
—
—
—
—
—
0
14
141
1323
—
Cyclic citrullinated peptide Ab [Units/volume] in Serum
53027-9 [3041942]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
0
6
141
1334
—
—
—
—
0
5
135
1265
Streptococcal pharyngitis
J02.0 [45533537]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
127
1219
—
—
—
—
—
—
Restoration involving the entire crown of the tooth
SFA40 [2001310361]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
127
1218
—
—
—
—
—
—
Physiotherapy
R4110 [2001310233]
4.7e-01
1.1e+00
—
—
—
9.6e-01
2.6e-01
cases:7.87%
controls:5.06%
cases:7.80%
controls:2.76%
—
—
—
—
—
—
cases:6.38%
controls:2.54%
cases:6.67%
controls:5.20%
10
62
117
1163
11
37
130
1303
—
—
—
9
34
132
1303
9
66
126
1204
pH of Serum or Plasma
2753-2 [3018418]
-1.0e+50
—
—
—
—
—
6.5e-01
cases:0.00%
controls:2.45%
—
—
—
—
—
—
—
—
—
—
cases:7.41%
controls:4.02%
0
30
127
1195
—
—
—
—
—
10
51
125
1219
promethazine, combinations
R06AD52 [21603489]
3.1e-01
-1.0e+50
—
—
—
—
—
cases:4.72%
controls:3.51%
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
6
43
121
1182
0
7
141
1333
—
—
—
—
—
Retina
C69.20 [2000501104]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.41%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
0
5
127
1220
0
6
141
1334
—
—
—
—
—
Lactate [Moles/volume] in Serum or Plasma
2524-7 [3014111]
—
1.3e+00
—
—
—
—
—
—
—
cases:3.55%
controls:0.97%
—
—
—
—
—
—
—
—
—
—
—
5
13
136
1327
—
—
—
—
—
Preventive oral health care, extensive
SCA03 [2001310304]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
0
5
141
1335
—
—
—
—
—
Appearance of Cerebral spinal fluid
10333-3 [3023410]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.22%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
0
15
127
1210
0
6
141
1334
—
—
—
—
—
etoricoxib; oral
M01AH05 [21603996]
6.8e-01
—
—
—
—
—
—
cases:3.94%
controls:2.04%
—
—
—
—
—
—
—
—
—
—
—
—
5
25
122
1200
—
—
—
—
—
—
Extensive initial psychiatric evaluation
IBA04 [2001304046]
—
—
—
—
—
-1.0e+50
9.2e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
cases:4.44%
controls:1.81%
—
—
—
—
—
0
5
141
1332
6
23
129
1247
Very extensive MRI examination of brain with high intensity magnet
AA1DG [2001300120]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.98%
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
0
12
127
1213
0
5
141
1335
—
—
—
—
—
Other specified congenital malformation syndromes, not elsewhere classified
Q87.88 [2000503569]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.65%
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
0
8
127
1217
0
7
141
1333
—
—
—
—
0
10
135
1260
Acute atopic conjunctivitis
H10.1 [45605605]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
0
6
135
1264
dexamethasone
S02BA06 [21605168]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
0
9
135
1261
Oral health check
SAB03 [2001310281]
3.1e-01
1.7e-01
—
—
—
2.0e-01
-2.4e-01
cases:9.45%
controls:7.10%
cases:5.67%
controls:4.85%
—
—
—
—
—
—
cases:5.67%
controls:4.71%
cases:11.85%
controls:14.57%
12
87
115
1138
8
65
133
1275
—
—
—
8
63
133
1274
16
185
119
1085
General anaesthesia
WX402 [2001310806]
—
—
—
—
—
—
8.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.37%
controls:4.80%
—
—
—
—
—
—
14
61
121
1209
Acute bronchiolitis due to respiratory syncytial virus
J21.0 [45552884]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
0
5
141
1335
—
—
—
—
—
Baker's yeast IgA Ab [Units/volume] in Serum
31032-6 [3004593]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
5
135
1265
Noninfective gastroenteritis and colitis, unspecified
K52.9 [45572215]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.87%
0
8
127
1217
—
—
—
—
—
0
11
135
1259
formoterol, glycopyrronium bromide and budesonide
R03AL11 [715850]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
0
7
141
1330
—
Treatment of chronic ulcer or burn
SPAT1148 [2001700249]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
127
1220
—
—
—
—
—
—
Bicarbonate [Moles/volume] standard in Capillary blood
19231-0 [3004490]
1.9e-01
-7.5e-03
—
—
—
3.4e-01
6.9e-01
cases:7.87%
controls:6.61%
cases:4.96%
controls:5.00%
—
—
—
—
—
—
cases:3.55%
controls:2.54%
cases:6.67%
controls:3.46%
10
81
117
1144
7
67
134
1273
—
—
—
5
34
136
1303
9
44
126
1226
Amino acids [Identifier] in Serum or Plasma
12468-5 [3013336]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
0
5
141
1332
—
chlorphenamine, combinations
R06AB54 [21603468]
4.7e-01
—
—
—
—
—
—
cases:5.51%
controls:3.51%
—
—
—
—
—
—
—
—
—
—
—
—
7
43
120
1182
—
—
—
—
—
—
Streptococcal tonsillitis
J03.0 [45601114]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.73%
—
—
—
—
—
—
0
22
135
1248
Chronic rhinitis
J31.0 [45572165]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
0
6
141
1334
—
—
—
—
—
Smooth muscle Ab [Titer] in Serum
8095-2 [3007566]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
127
1219
—
—
—
—
—
—
lidocaine
C05AD01 [21601618]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
0
7
135
1263
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
-6.7e-03
-3.9e-02
—
—
—
4.4e-01
-5.0e-02
cases:15.75%
controls:15.84%
cases:12.77%
controls:13.21%
—
—
—
—
—
—
cases:13.48%
controls:9.12%
cases:18.52%
controls:19.29%
20
194
107
1031
18
177
123
1163
—
—
—
19
122
122
1215
25
245
110
1025
Emergency Medicine
93 [38004510]
—
—
-1.0e+50
—
-1.0e+50
6.1e-01
-1.6e-01
—
—
—
—
cases:0.00%
controls:0.67%
—
—
cases:0.00%
controls:0.67%
cases:7.80%
controls:4.41%
cases:15.56%
controls:17.72%
—
—
0
9
141
1331
—
0
9
141
1331
11
59
130
1278
21
225
114
1045
Urination problems other
U05 [2002001140]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
5
135
1265
Counselling and guidance which enhance independent living
R2130 [2001310196]
-2.3e-01
6.2e-01
—
—
—
—
—
cases:4.72%
controls:5.88%
cases:3.55%
controls:1.94%
—
—
—
—
—
—
—
—
—
—
6
72
121
1153
5
26
136
1314
—
—
—
—
—
Migraine, unspecified
G43.9 [45595943]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
5
135
1265
chlorhexidine
D09AA12 [21602275]
2.7e-01
—
—
—
—
—
—
cases:5.51%
controls:4.24%
—
—
—
—
—
—
—
—
—
—
—
—
7
52
120
1173
—
—
—
—
—
—
Orthopedic Surgery
20 [38004465]
—
1.3e+00
—
—
—
—
—
—
—
cases:3.55%
controls:0.97%
—
—
—
—
—
—
—
—
—
—
—
5
13
136
1327
—
—
—
—
—
Troponin I.cardiac [Mass/volume] in Serum or Plasma
10839-9 [3021337]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
—
—
—
—
—
0
15
141
1325
—
—
—
—
—
ephedrine, combinations
A08AA56 [21600692]
3.9e-01
—
—
—
—
—
—
cases:3.94%
controls:2.69%
—
—
—
—
—
—
—
—
—
—
—
—
5
33
122
1192
—
—
—
—
—
—
CD3 cells/Lymphocytes in Blood
90304-7 [1175426]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
0
9
141
1328
—
Counselling related to known health issue
SPAT1310 [2001700411]
—
—
—
—
—
—
3.8e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.67%
controls:4.65%
—
—
—
—
—
—
9
59
126
1211
Albumin [Presence] in Urine by Test strip
50949-7 [3029937]
1.0e+00
—
—
—
—
—
—
cases:4.72%
controls:1.80%
—
—
—
—
—
—
—
—
—
—
—
—
6
22
121
1203
—
—
—
—
—
—
Herpes virus 6 IgM Ab [Presence] in Cerebral spinal fluid
42915-9 [3034368]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
127
1220
—
—
—
—
—
—
granisetron; oral, parenteral, transdermal
A04AA02 [21600494]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.06%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
0
13
127
1212
0
6
141
1334
—
—
—
—
—
B lymphocytes [#/volume] in Blood
11130-2 [3000060]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
0
7
141
1330
—
Psychiatric treatment plan, standard
ICB01 [2001304098]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.19%
controls:1.50%
—
—
—
—
—
—
7
19
128
1251
Conditioning play audiometry
6339003 [4272008]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
0
7
135
1263
isosorbide mononitrate; oral
C01DA14 [21600324]
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
—
cases:0.00%
controls:1.14%
cases:0.00%
controls:0.90%
—
—
—
—
cases:0.00%
controls:0.60%
cases:0.00%
controls:0.97%
—
—
0
14
127
1211
0
12
141
1328
—
—
0
8
141
1332
0
13
141
1324
—
Pharmacy visit
OMOP4822462 [581458]
-2.2e-02
-1.8e-01
-2.0e-01
—
2.0e-01
2.7e-01
3.2e-01
cases:91.34%
controls:91.51%
cases:64.54%
controls:68.58%
cases:24.82%
controls:28.66%
—
—
cases:31.91%
controls:27.69%
cases:73.05%
controls:67.39%
cases:89.63%
controls:86.30%
116
1121
11
104
91
919
50
421
35
384
106
956
—
45
371
96
969
103
901
38
436
121
1096
14
174
Fracture of tooth, open
S02.51 [45755762]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
127
1219
—
—
—
—
—
—
Difficulties in perfomrming procedure
ZXD30 [2001311389]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
5
135
1265
hydrocortisone
S02BA01 [21605166]
-2.8e-01
9.6e-02
-1.0e+50
—
—
1.0e-01
-6.0e-01
cases:7.87%
controls:10.20%
cases:4.26%
controls:3.88%
cases:0.00%
controls:0.52%
—
—
—
—
cases:3.55%
controls:3.22%
cases:5.19%
controls:9.06%
10
125
117
1100
6
52
135
1288
0
7
141
1333
—
—
5
43
136
1294
7
115
128
1155
General medical examination
Z00.0 [45585791]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
0
8
141
1329
—
dexamethasone
C05AA09 [21601613]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
0
9
135
1261
Natriuretic peptide B [Mass/volume] in Serum or Plasma
30934-4 [3011960]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.97%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
0
13
141
1327
—
—
—
—
0
10
135
1260
Chronic asthma and similar chronic obstructive pulmonary diseases
203 [2001600201]
5.7e-02
—
—
—
—
—
4.9e-01
cases:5.51%
controls:5.22%
—
—
—
—
—
—
—
—
—
—
cases:4.44%
controls:2.76%
7
64
120
1161
—
—
—
—
—
6
35
129
1235
Neutrophils/Leukocytes in Blood
26511-6 [3018010]
8.6e-02
-1.6e-01
—
—
—
1.1e-01
2.1e-01
cases:10.24%
controls:9.47%
cases:7.09%
controls:8.21%
—
—
—
—
—
—
cases:6.38%
controls:5.76%
cases:14.07%
controls:11.73%
13
116
114
1109
10
110
131
1230
—
—
—
9
77
132
1260
19
149
116
1121
fluticasone furoate; nasal
R01AD12 [21605053]
1.0e-01
3.4e-02
-1.0e+50
—
—
—
-5.5e-01
cases:7.09%
controls:6.45%
cases:3.55%
controls:3.43%
cases:0.00%
controls:0.52%
—
—
—
—
—
—
cases:5.93%
controls:9.84%
9
79
118
1146
5
46
136
1294
0
7
141
1333
—
—
—
8
125
127
1145
Mouth/tongue/lip symptom/complaint
D20 [2002000319]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
0
5
141
1332
—
salmeterol and fluticasone
R03AK06 [21603280]
—
1.3e+00
—
—
—
1.2e+00
4.7e-01
—
—
cases:4.96%
controls:1.34%
—
—
—
—
—
—
cases:4.96%
controls:1.57%
cases:5.19%
controls:3.31%
—
7
18
134
1322
—
—
—
7
21
134
1316
7
42
128
1228
Periodontal treatment
SDA03 [2001310328]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
0
7
141
1333
—
—
—
—
—
Removal of fixed orthodontic appliance with at most 6 brackets
SJC40 [2001310434]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
0
7
141
1333
—
—
—
0
9
141
1328
—
12 lead EKG panel
34534-8 [3044889]
4.2e-01
—
—
—
-1.0e+50
7.4e-01
5.8e-01
cases:3.94%
controls:2.61%
—
—
—
—
—
—
cases:0.00%
controls:0.45%
cases:3.55%
controls:1.72%
cases:8.15%
controls:4.72%
5
32
122
1193
—
—
—
0
6
141
1334
5
23
136
1314
11
60
124
1210
Speech therapy
R4130 [2001310235]
—
—
—
—
—
—
1.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.70%
controls:1.26%
—
—
—
—
—
—
5
16
130
1254
varicella, live attenuated
J07BK01 [21601362]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
0
8
141
1332
—
—
—
—
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
2.8e-01
5.0e-01
—
—
-1.0e+50
—
1.4e-01
cases:7.87%
controls:6.04%
cases:4.26%
controls:2.61%
—
—
—
—
cases:0.00%
controls:0.52%
—
—
cases:11.85%
controls:10.47%
10
74
117
1151
6
35
135
1305
—
—
0
7
141
1333
—
16
133
119
1137
Teeth/gum disease
D82 [2002000380]
—
—
-1.0e+50
—
—
-1.0e+50
-1.8e-02
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
cases:0.00%
controls:1.94%
cases:5.19%
controls:5.28%
—
—
0
5
141
1335
—
—
0
26
141
1311
7
67
128
1203
Calcium [Moles/volume] corrected for albumin in Serum or Plasma
29265-6 [3020059]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
0
7
135
1263
Cardiac ultrasound examination through oesophagus
FM1BE [2001303285]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
—
0
10
141
1330
—
—
—
—
—
Bruise/contusion
S16 [2002000981]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
0
8
135
1262
Sampling
SPAT1263 [2001700364]
5.2e-01
—
—
—
—
—
-2.9e-01
cases:5.51%
controls:3.35%
—
—
—
—
—
—
—
—
—
—
cases:4.44%
controls:5.83%
7
41
120
1184
—
—
—
—
—
6
74
129
1196
Coloscopy
UJF32 [2001305029]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
—
0
10
141
1330
—
—
—
—
—
Removal of sutures
SPAT1153 [2001700254]
—
—
—
—
—
—
8.0e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.44%
controls:2.05%
—
—
—
—
—
—
6
26
129
1244
Procedure duration 50 to 59 minutes
ZXE06 [2001311400]
—
9.9e-01
—
—
—
—
—
—
—
cases:3.55%
controls:1.34%
—
—
—
—
—
—
—
—
—
—
—
5
18
136
1322
—
—
—
—
—
acetylsalicylic acid; oral
B01AC06 [21600991]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
0
7
141
1333
—
—
—
0
5
141
1332
—
covid-19, RNA-based vaccine
J07BN01 [954934]
—
—
—
—
—
—
-3.6e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.89%
controls:12.28%
—
—
—
—
—
—
12
156
123
1114
Dizziness and giddiness
R42 [45568132]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
127
1218
—
—
—
—
—
—
paracetamol, combinations excl. psycholeptics
N02BE51 [21604348]
3.3e-01
-1.0e+50
—
—
—
—
—
cases:4.72%
controls:3.43%
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
6
42
121
1183
0
5
141
1335
—
—
—
—
—
fluticasone; inhalant
R03BA05 [21603288]
2.0e-01
-1.5e-01
-1.0e+50
—
-1.0e+50
3.4e-01
1.2e-01
cases:11.81%
controls:9.88%
cases:4.26%
controls:4.93%
cases:0.00%
controls:0.90%
—
—
cases:0.00%
controls:1.12%
cases:5.67%
controls:4.11%
cases:7.41%
controls:6.61%
15
121
112
1104
6
66
135
1274
0
12
141
1328
—
0
15
141
1325
8
55
133
1282
10
84
125
1186
Opening and preparing the root canals
SGA02 [2001310380]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
5
135
1265
Embedded teeth
K01.0 [45548133]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
0
7
135
1263
Repeated or continuing anesthesia shots throug a catheter
WX602 [2001310813]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
127
1217
—
—
—
—
—
—
Lactate [Moles/volume] in Capillary blood
19239-3 [3028271]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
0
5
141
1335
—
—
—
—
0
5
135
1265
Dental examination
Z01.2 [45581002]
-4.4e-01
—
-1.0e+50
—
-1.0e+50
-2.9e-01
-9.5e-02
cases:6.30%
controls:9.47%
—
—
cases:0.00%
controls:0.37%
—
—
cases:0.00%
controls:0.37%
cases:4.26%
controls:5.61%
cases:17.78%
controls:19.21%
8
116
119
1109
—
0
5
141
1335
—
0
5
141
1335
6
75
135
1262
24
244
111
1026
chlorhexidine
S02AA09 [21605155]
2.7e-01
—
—
—
—
—
—
cases:5.51%
controls:4.24%
—
—
—
—
—
—
—
—
—
—
—
—
7
52
120
1173
—
—
—
—
—
—
Provision of support and information to patient’s family members
SPAT1245 [2001700346]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
127
1219
—
—
—
—
—
—
methotrexate
L01BA01 [21601423]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
cases:0.00%
controls:1.12%
—
—
—
0
14
141
1326
—
—
—
0
15
141
1322
—
opium derivatives and expectorants
R05FA02 [21603439]
3.1e-01
-1.0e+50
—
—
—
—
—
cases:4.72%
controls:3.51%
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
6
43
121
1182
0
7
141
1333
—
—
—
—
—
Tissue transglutaminase IgA Ab [Units/volume] in Serum
31017-7 [3019050]
-2.3e-02
—
—
—
—
—
-1.3e-01
cases:5.51%
controls:5.63%
—
—
—
—
—
—
—
—
—
—
cases:5.93%
controls:6.69%
7
69
120
1156
—
—
—
—
—
8
85
127
1185
Iron/Transferrin [Ratio] in Serum or Plasma
60517-0 [40763571]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
0
6
141
1334
—
—
Genetic counselling
Z31.5 [45590715]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:4.16%
cases:0.00%
controls:2.46%
—
—
—
—
—
—
cases:0.00%
controls:1.05%
—
—
0
51
127
1174
0
33
141
1307
—
—
—
0
14
141
1323
—
Office Visit
OMOP4822458 [581477]
-3.9e-01
-6.3e-01
-1.0e+50
—
-1.0e+50
-6.8e-01
-8.5e-01
cases:13.39%
controls:18.53%
cases:5.67%
controls:10.15%
cases:0.00%
controls:1.57%
—
—
cases:0.00%
controls:1.12%
cases:4.26%
controls:8.08%
cases:7.41%
controls:15.83%
17
227
110
998
8
136
133
1204
0
21
141
1319
—
0
15
141
1325
6
108
135
1229
10
201
125
1069
Type 1 diabetes mellitus
E10 [45576436]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
0
5
141
1335
—
—
—
0
6
141
1331
—
pseudoephedrine; oral
R01BA02 [21603210]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.79%
—
—
—
—
—
—
0
10
135
1260
Implementation of speech therapy rehabilitation plan
SPAT1224 [2001700325]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
0
9
135
1261
Major dressing of wound of skin of lower limb
QDB10 [2001309970]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
0
5
141
1335
—
—
—
—
—
prednisone; oral
H02AB07 [21602735]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
cases:0.00%
controls:0.39%
—
—
—
—
—
0
5
141
1332
0
5
135
1265
measles, combinations with mumps, rubella and varicella, live attenuated
J07BD54 [21601346]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.73%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
127
1216
—
—
—
—
—
—
Leukocytes [#/volume] in Blood
26464-8 [3010813]
-1.3e-01
3.8e-02
3.0e-01
—
3.2e-01
2.5e-01
-7.2e-02
cases:18.90%
controls:20.98%
cases:19.86%
controls:19.25%
cases:5.67%
controls:4.25%
—
—
cases:6.38%
controls:4.70%
cases:18.44%
controls:14.96%
cases:25.93%
controls:27.32%
24
257
103
968
28
258
113
1082
8
57
133
1283
—
9
63
132
1277
26
200
115
1137
35
347
100
923
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
—
—
-1.0e+50
—
—
—
8.3e-01
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
cases:7.41%
controls:3.39%
—
—
0
7
141
1333
—
—
—
10
43
125
1227
Epispadias
Q64.0 [45534395]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
5
135
1265
Rheumatoid factor [Units/volume] in Serum or Plasma
11572-5 [3021614]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
0
7
141
1333
—
—
—
—
—
IgM [Mass/volume] in Serum or Plasma
2472-9 [3028026]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.97%
—
—
—
—
—
—
—
0
13
141
1324
—
insulin glargine; parenteral
A10AE04 [21600739]
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.98%
cases:0.00%
controls:1.04%
—
—
—
—
cases:0.00%
controls:0.45%
cases:0.00%
controls:1.65%
cases:0.00%
controls:4.88%
0
12
127
1213
0
14
141
1326
—
—
0
6
141
1334
0
22
141
1315
0
62
135
1208
Epithelial cells.squamous [#/volume] in Urine by Automated count
51486-9 [3029879]
—
—
—
—
—
—
1.9e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.93%
controls:4.96%
—
—
—
—
—
—
8
63
127
1207
IgG/Albumin [Mass Ratio] in Cerebral spinal fluid
2470-3 [3007798]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
127
1219
—
—
—
—
—
—
Speech disorder
N19 [2002000730]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
0
7
141
1330
—
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
1.1e+00
—
—
—
—
—
—
cases:5.51%
controls:1.88%
—
—
—
—
—
—
—
—
—
—
—
—
7
23
120
1202
—
—
—
—
—
—
Fracture of lower end of radius
S52.5 [45573842]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.81%
—
—
—
—
—
—
0
23
135
1247
lenograstim; parenteral
L03AA10 [21603854]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.82%
cases:0.00%
controls:0.37%
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
0
10
127
1215
0
5
141
1335
—
—
—
0
7
141
1330
—
Essential (primary) hypertension
I10 [45591453]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:2.61%
cases:0.00%
controls:1.04%
—
—
—
—
—
—
—
—
—
—
0
32
127
1193
0
14
141
1326
—
—
—
—
—
General Practice
1 [38004446]
-3.7e-01
—
—
—
—
7.8e-01
3.7e-01
cases:7.87%
controls:11.02%
—
—
—
—
—
—
—
—
cases:7.09%
controls:3.37%
cases:10.37%
controls:7.40%
10
135
117
1090
—
—
—
—
10
45
131
1292
14
94
121
1176
Foot and toes X-ray examination
NH3AA [2001308267]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
127
1218
—
—
—
—
—
—
Albumin [Mass/volume] in Cerebral spinal fluid
1746-7 [3024474]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
127
1218
—
—
—
—
—
—
Other specified special examinations
Z01.8 [45581003]
6.0e-01
—
—
—
—
—
8.1e-01
cases:7.87%
controls:4.49%
—
—
—
—
—
—
—
—
—
—
cases:8.89%
controls:4.17%
10
55
117
1170
—
—
—
—
—
12
53
123
1217
Polyuria
R35 [45539331]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
0
6
135
1264
Other healthcare associate professional
Z3229 [2001311561]
4.0e-01
—
—
—
—
—
—
cases:5.51%
controls:3.76%
—
—
—
—
—
—
—
—
—
—
—
—
7
46
120
1179
—
—
—
—
—
—
Vomiting
D10 [2002000309]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
0
5
141
1335
—
—
—
—
—
Foot/toe symptom/complaint
L17 [2002000641]
—
—
—
—
—
-1.0e+50
-2.1e-02
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
cases:3.70%
controls:3.78%
—
—
—
—
—
0
11
141
1326
5
48
130
1222
Feeling ill
A05 [2002000146]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.90%
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
0
11
127
1214
0
7
141
1333
—
—
—
—
—
Abdominal ultrasound examination
JN3AE [2001305555]
4.2e-01
—
—
—
—
-1.0e+50
3.1e-01
cases:5.51%
controls:3.67%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
cases:3.70%
controls:2.76%
7
45
120
1180
—
—
—
—
0
8
141
1329
5
35
130
1235
topiramate; oral
N03AX11 [21604433]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
cases:0.00%
controls:0.75%
cases:0.00%
controls:0.79%
—
0
11
141
1329
—
—
—
0
10
141
1327
0
10
135
1260
azelaic acid; ointment
D10AX03 [21602314]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
—
—
—
—
—
—
0
7
135
1263
sitagliptin; oral
A10BH01 [21600784]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
cases:0.00%
controls:0.55%
—
—
—
—
—
0
6
141
1331
0
7
135
1263
Other disturbance in the tooth eruption
K00.68 [2000502648]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.90%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.18%
0
11
127
1214
—
—
—
—
—
0
15
135
1255
Allergy, unspecified
T78.4 [45580373]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.06%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.63%
0
13
127
1212
—
—
—
—
—
0
8
135
1262
CD3-CD16+CD56+ (Natural killer) cells/cells in Blood
8112-5 [3027831]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
—
0
9
141
1328
—
amoxicillin; oral, parenteral
J01CA04 [21602823]
-9.3e-02
-2.5e-03
—
—
—
4.7e-01
-5.3e-02
cases:48.03%
controls:50.37%
cases:14.89%
controls:14.93%
—
—
—
—
—
—
cases:18.44%
controls:12.42%
cases:26.67%
controls:27.72%
61
617
66
608
21
200
120
1140
—
—
—
26
166
115
1171
36
352
99
918
Other specified osteochondrodysplasias
Q78.88 [2000503497]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
cases:0.00%
controls:0.52%
cases:0.00%
controls:0.71%
—
0
7
141
1333
—
—
—
0
7
141
1330
0
9
135
1261
digoxin; oral, parenteral
C01AA05 [21600234]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
5
135
1265
cromoglicic acid; nasal
R01AC01 [21605033]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.57%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.55%
0
7
127
1218
—
—
—
—
—
0
7
135
1263
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
4.0e-01
1.6e-01
—
—
-1.0e+50
4.2e-01
2.4e-01
cases:6.30%
controls:4.33%
cases:4.96%
controls:4.25%
—
—
—
—
cases:0.00%
controls:0.67%
cases:5.67%
controls:3.81%
cases:10.37%
controls:8.35%
8
53
119
1172
7
57
134
1283
—
—
0
9
141
1331
8
51
133
1286
14
106
121
1164
Egg white IgE Ab [Units/volume] in Serum
6106-9 [3014599]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.90%
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
0
12
141
1328
—
—
—
0
6
141
1331
—
Cardiac output
82799009 [4221102]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
127
1220
—
—
—
—
—
—
Hospital outpatient
ZY010 [2001311599]
3.3e-01
—
—
—
—
—
—
cases:3.94%
controls:2.86%
—
—
—
—
—
—
—
—
—
—
—
—
5
35
122
1190
—
—
—
—
—
—
Ankyloglossia
Q38.1 [45597124]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
127
1215
—
—
—
—
—
—
metoprolol; oral, parenteral
C07AB02 [21601684]
—
-1.0e+50
—
—
-1.0e+50
—
—
—
—
cases:0.00%
controls:0.90%
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
0
12
141
1328
—
—
0
5
141
1335
—
—
Leukocytes [#/volume] in Cerebral spinal fluid
26465-5 [3016543]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.22%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
0
15
127
1210
0
6
141
1334
—
—
—
—
—
ECG with 12 standard connections
XF400 [2001303368]
4.1e-01
4.5e-01
-1.0e+50
—
—
—
2.2e-01
cases:7.87%
controls:5.39%
cases:4.26%
controls:2.76%
cases:0.00%
controls:0.60%
—
—
—
—
—
—
cases:3.70%
controls:2.99%
10
66
117
1159
6
37
135
1303
0
8
141
1332
—
—
—
5
38
130
1232
25-hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
46269-7 [3051659]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
5
135
1265
Hypersensitivity skin testing
268377001 [4147813]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
—
—
—
0
5
141
1335
—
—
—
—
—
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
—
—
—
—
—
—
—
—
0
8
141
1332
—
—
—
—
—
mometasone; nasal
R01AD09 [21605051]
-3.3e-01
—
-1.0e+50
—
—
3.1e-01
4.9e-02
cases:4.72%
controls:6.45%
—
—
cases:0.00%
controls:0.37%
—
—
—
—
cases:3.55%
controls:2.62%
cases:9.63%
controls:9.21%
6
79
121
1146
—
0
5
141
1335
—
—
5
35
136
1302
13
117
122
1153
Psychiatric family contact
IGP01 [2001304317]
—
—
—
—
—
—
9.3e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.70%
controls:1.50%
—
—
—
—
—
—
5
19
130
1251
clindamycin; oral, parenteral
J01FF01 [21602985]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
0
6
141
1331
—
mometasone
D07AC13 [21602132]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
0
7
141
1330
—
Fall on same level from slipping, tripping and stumbling
W01 [45756243]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
—
—
—
—
—
—
—
—
—
0
10
141
1330
—
—
—
—
—
Hand Surgery
40 [38004480]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.90%
cases:0.00%
controls:0.37%
—
—
—
—
—
—
cases:0.00%
controls:0.52%
cases:0.00%
controls:0.87%
0
11
127
1214
0
5
141
1335
—
—
—
0
7
141
1330
0
11
135
1259
Cystic fibrosis with intestinal manifestations
E84.1 [45605436]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
0
5
135
1265
Myalgia
M79.1 [45587062]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.47%
—
—
—
—
—
—
0
6
135
1264
Otitis media, unspecified
H66.9 [45547965]
5.3e-01
-1.0e+50
—
—
—
—
4.1e-01
cases:10.24%
controls:6.29%
cases:0.00%
controls:2.09%
—
—
—
—
—
—
—
—
cases:4.44%
controls:2.99%
13
77
114
1148
0
28
141
1312
—
—
—
—
6
38
129
1232
diclofenac; oral, parenteral, rectal
M01AB05 [21603945]
6.6e-01
—
—
—
—
—
1.9e-01
cases:5.51%
controls:2.94%
—
—
—
—
—
—
—
—
—
—
cases:4.44%
controls:3.70%
7
36
120
1189
—
—
—
—
—
6
47
129
1223
hydroxyzine; oral, parenteral
N05BB01 [21604590]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
cases:0.00%
controls:0.60%
—
—
—
0
11
141
1329
—
—
—
0
8
141
1329
—
Adenotomy
EMB30 [2001302268]
-2.7e-01
—
—
—
—
—
—
cases:4.72%
controls:6.12%
—
—
—
—
—
—
—
—
—
—
—
—
6
75
121
1150
—
—
—
—
—
—
Balanoposthitis
N48.1 [45567850]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
0
11
141
1329
—
—
—
—
—
Other gastroenteritis and colitis of infectious and unspecified origin
A09 [45605189]
1.5e-01
—
—
—
—
—
—
cases:4.72%
controls:4.08%
—
—
—
—
—
—
—
—
—
—
—
—
6
50
121
1175
—
—
—
—
—
—
miconazole
D01AC02 [21601921]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.63%
—
—
—
—
—
—
0
8
135
1262
Acute maxillary sinusitis
J01.0 [45601112]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.67%
—
—
—
—
—
—
cases:0.00%
controls:0.67%
—
—
—
0
9
141
1331
—
—
—
0
9
141
1328
—
Implementation of physical therapy rehabilitation plan
SPAT1223 [2001700324]
1.2e+00
—
—
—
—
—
2.4e-01
cases:4.72%
controls:1.47%
—
—
—
—
—
—
—
—
—
—
cases:4.44%
controls:3.54%
6
18
121
1207
—
—
—
—
—
6
45
129
1225
mirtazapine; oral
N06AX11 [21604740]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.44%
controls:1.02%
—
—
—
—
—
—
6
13
129
1257
Audiology
64 [38004489]
-2.0e-01
6.6e-01
—
—
-1.0e+50
4.0e-01
3.9e-01
cases:4.72%
controls:5.71%
cases:3.55%
controls:1.87%
—
—
—
—
cases:0.00%
controls:0.45%
cases:3.55%
controls:2.39%
cases:5.93%
controls:4.09%
6
70
121
1155
5
25
136
1315
—
—
0
6
141
1334
5
32
136
1305
8
52
127
1218
English Walnut IgE Ab [Units/volume] in Serum
7765-1 [3011841]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.41%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
127
1220
—
—
—
—
—
—
Bordetella pertussis IgA Ab [Units/volume] in Serum
9362-5 [3025149]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.37%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
0
5
141
1335
—
—
—
—
0
5
135
1265
Ear microscopy
UDC00 [2001301558]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.79%
—
—
—
—
—
—
—
—
—
—
—
0
24
141
1316
—
—
—
—
—
Diabetes insulin dependent
T89 [2002001130]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.73%
cases:0.00%
controls:0.75%
—
—
—
—
—
—
cases:0.00%
controls:0.75%
—
—
0
9
127
1216
0
10
141
1330
—
—
—
0
10
141
1327
—

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
28
150
2.01
2.69
2.0
2.5
4.29
3.77
u/l
0.18
16
88
23
121
2.02
2.32
2.1
2.7
6.69
5.46
iu/l
0.23
15
64
0
56
0.00
2.10
0.0
1.2
—
—
—
0
0
74
558
1.53
2.09
5.0
6.7
12.61
9.38
e6/l
0.23
48
376
18
94
2.01
1.87
2.1
1.6
—
—
—
0
0
77
603
1.46
1.75
4.0
3.8
0.00
0.00
estimate
—
10
86
5
13
3.92
1.72
1.2
1.1
—
—
—
0
0
76
596
1.45
1.71
3.9
3.8
0.00
0.00
estimate
—
10
94
64
490
1.46
1.62
4.3
5.4
7.50
19.77
e6/l
1.48
49
371
60
456
1.46
1.57
4.0
5.0
0.39
0.17
e6/l
0.32
46
334
25
155
1.70
1.56
3.7
2.6
—
—
—
0
0
67
524
1.42
1.50
3.8
3.6
6.52
6.23
ph
1.03
27
224
74
595
1.39
1.40
3.9
3.8
0.00
0.00
estimate
—
10
98
105
896
1.37
1.38
6.4
7.9
123.39
133.07
u/l
0.52
97
859
24
156
1.61
1.27
1.2
2.2
—
—
—
0
0
20
124
1.68
1.26
3.3
2.6
0.52
0.60
ug/l
—
8
61
9
45
2.05
1.25
6.3
6.0
2.11
2.16
ug/l
—
9
45
46
348
1.42
1.22
7.7
9.2
—
—
—
0
0
40
295
1.45
1.21
4.5
3.1
1.02
1.02
kg/l
0.27
21
175
89
752
1.34
1.19
11.9
16.9
1.22
1.22
mmol/l
0.29
84
726
35
254
1.46
1.15
4.8
4.0
0.00
0.01
estimate
—
9
88
10
179
0.53
1.12
1.3
1.5
—
—
—
0
0
44
341
1.37
1.02
3.2
3.9
117.51
102.44
ug/g
0.16
35
297
41
315
1.38
1.00
3.4
4.7
1.42
0.38
e6/l
0.78
24
168
0
30
0.00
0.98
0.0
1.2
—
—
—
0
0
33
245
1.42
0.97
3.1
5.1
1.32
1.94
mg/l
0.43
23
183
39
299
1.38
0.96
2.3
3.7
545.24
613.00
mosm/kgh2o
0.94
34
272
29
211
1.44
0.95
1.4
2.0
—
—
—
0
0
6
28
2.18
0.92
5.5
4.9
0.33
0.71
index
—
6
28
5
103
0.47
0.92
1.2
1.3
—
—
—
0
0
134
1226
1.30
0.91
4.5
3.7
2.02
2.05
mu/l
0.09
126
1163
39
491
0.74
0.88
1.8
2.0
—
—
—
0
0
47
378
1.32
0.86
5.2
6.8
1.11
1.16
inr
0.59
39
317
63
529
1.28
0.84
8.0
9.7
38.22
38.03
g/l
0.08
63
508
0
26
0.00
0.79
0.0
1.0
—
—
—
0
0
14
91
1.58
0.77
1.7
3.1
—
—
—
0
0
152
1426
1.30
0.77
13.5
17.2
139.41
139.59
mmol/l
0.57
144
1404
152
1427
1.30
0.76
13.6
17.2
3.97
3.98
mmol/l
0.18
142
1394
47
385
1.29
0.75
8.7
10.1
7.41
7.41
ph
0.90
40
305
7
40
1.78
0.72
1.3
1.4
2.91
12.90
u/ml
—
7
40
10
155
0.63
0.69
1.2
1.5
—
—
—
0
0
41
335
1.28
0.67
2.3
5.4
7.38
7.39
ph
0.14
31
226
118
1085
1.22
0.66
3.7
3.8
4.34
4.41
mmol/l
0.39
113
1043
115
1056
1.22
0.65
4.1
3.3
14.59
14.76
pmol/l
0.32
107
986
0
20
0.00
0.60
0.0
4.2
—
4.91
—
0
20
87
782
1.20
0.60
11.0
14.9
1.22
1.22
mmol/l
0.17
80
730
44
372
1.24
0.55
4.4
3.2
0.00
0.00
estimate
—
9
88
37
307
1.25
0.55
2.9
5.2
—
—
—
0
0
9
61
1.50
0.54
2.2
2.3
—
—
—
0
0
9
61
1.50
0.54
2.2
2.3
—
—
—
0
0
9
61
1.50
0.54
2.2
2.3
—
—
—
0
0
9
61
1.50
0.54
2.2
2.3
—
—
—
0
0
28
341
0.79
0.50
3.0
4.0
2.67
2.49
mg/l
0.26
28
320
18
231
0.76
0.48
3.9
4.2
251.97
1244.21
ng/l
1.36
13
159
39
332
1.22
0.46
1.5
2.2
—
—
—
0
0
160
1539
1.22
0.46
10.1
8.9
—
—
—
0
0
17
218
0.76
0.45
2.2
1.9
—
—
—
0
0
5
31
1.63
0.43
1.4
4.8
4.12
2.93
e9/l
—
5
31
45
392
1.19
0.43
1.3
1.4
—
—
—
0
0
47
412
1.19
0.42
2.4
2.4
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
16
0.00
0.41
0.0
2.1
—
99.56
—
0
16
0
16
0.00
0.41
0.0
9.3
—
—
—
0
0
0
16
0.00
0.41
0.0
1.2
—
—
—
0
0
0
16
0.00
0.41
0.0
1.2
—
0.59
—
0
11
0
17
0.00
0.41
0.0
1.1
—
262.45
—
0
17
0
17
0.00
0.41
0.0
1.4
—
34.00
—
0
5
0
17
0.00
0.41
0.0
1.4
—
17.00
—
0
5
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
7
102
0.67
0.40
25.6
13.1
1.51
1.34
%
—
7
102
7
105
0.65
0.40
13.6
21.7
0.79
0.67
%
—
7
105
52
463
1.17
0.39
3.1
4.2
—
—
estimate
—
0
0
15
116
1.32
0.38
3.1
6.6
0.60
0.78
%
—
5
46
33
283
1.20
0.37
8.3
7.5
—
—
—
0
0
9
70
1.30
0.37
1.2
1.2
—
—
—
0
0
20
243
0.80
0.36
1.4
1.7
—
—
—
0
0
51
457
1.16
0.35
1.9
2.1
1.37
1.35
mmol/l
0.05
45
431
31
268
1.19
0.33
2.0
3.2
0.00
0.00
estimate
—
9
79
23
271
0.83
0.32
12.7
14.7
0.85
0.80
mmol/l
0.31
23
264
7
52
1.36
0.31
1.0
1.1
—
—
—
0
0
7
99
0.70
0.31
25.6
13.4
0.81
0.58
%
—
7
99
102
965
1.12
0.30
3.2
2.9
5.44
5.61
mmol/l
1.34
95
890
31
271
1.17
0.29
1.8
3.1
224.16
383.23
u/l
0.62
31
271
7
57
1.24
0.29
1.0
1.2
—
—
—
0
0
17
204
0.82
0.28
15.9
18.8
1.31
1.36
mmol/l
0.13
17
198
27
235
1.17
0.27
1.5
1.9
—
—
—
0
0
159
1549
1.14
0.26
11.6
13.8
65.74
67.37
umol/l
0.40
153
1530
27
236
1.17
0.26
1.5
2.0
—
—
—
0
0
27
237
1.16
0.25
1.6
2.1
—
—
—
0
0
9
77
1.18
0.24
1.6
3.9
—
—
—
0
0
113
1084
1.10
0.24
4.1
3.8
2.75
2.72
mmol/l
0.16
108
1036
21
181
1.18
0.23
1.9
2.4
—
—
—
0
0
112
1075
1.10
0.23
3.8
3.7
1.29
1.31
mmol/l
0.27
106
1028
5
39
1.29
0.23
1.2
1.7
289.40
294.52
mosm/kgh2o
—
5
23
28
249
1.15
0.22
1.3
1.6
—
—
—
0
0
15
126
1.21
0.21
3.8
7.5
21.93
22.94
s
0.46
15
126
8
102
0.78
0.21
1.1
1.8
18.25
21.33
ng/l
—
8
102
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
3.8
—
4.44
—
0
11
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
99.20
—
0
10
25
221
1.15
0.21
1.5
2.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.1
—
7.13
—
0
12
0
12
0.00
0.21
0.0
1.9
—
6.96
—
0
12
0
12
0.00
0.21
0.0
1.1
—
218.84
—
0
12
104
998
1.09
0.21
7.6
13.1
0.24
0.23
e9/l
0.08
88
825
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
15
176
0.84
0.21
3.1
7.3
55.40
66.62
e9/l
—
8
112
156
1525
1.11
0.20
15.4
19.1
13.30
13.12
%
1.12
151
1512
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
0
14
0.00
0.20
0.0
1.6
—
0.44
—
0
14
57
608
0.91
0.20
1.6
1.9
1.67
1.82
g/l
0.33
29
314
6
49
1.23
0.20
1.2
1.8
0.18
4.90
u/ml
—
6
49
155
1518
1.10
0.18
9.7
11.2
34.00
31.31
u/l
0.51
147
1482
21
236
0.88
0.18
9.1
6.8
6.54
8.36
umol/l
0.41
21
199
65
685
0.92
0.17
2.5
2.6
—
—
—
0
0
5
68
0.73
0.17
1.0
1.0
1.45
1.43
g/l
—
5
68
5
70
0.71
0.17
1.0
1.2
0.88
0.92
g/l
—
5
70
8
70
1.15
0.16
1.1
1.2
—
—
—
0
0
8
72
1.12
0.16
1.1
1.2
—
—
—
0
0
19
213
0.88
0.15
13.2
13.8
106.21
104.91
mmol/l
0.94
19
213
17
192
0.87
0.15
1.5
1.3
6.46
3.34
u/ml
0.31
12
149
61
641
0.93
0.15
2.1
2.0
2.34
2.88
u/ml
—
8
117
156
1583
0.93
0.12
15.4
18.1
338.10
337.56
g/l
0.27
156
1569
13
114
1.15
0.12
1.6
1.5
—
—
—
0
0
41
387
1.08
0.12
2.8
4.1
—
—
—
0
0
20
217
0.91
0.10
2.8
2.8
—
—
—
0
0
37
390
0.94
0.09
11.7
14.2
—
—
—
0
0
178
1795
0.90
0.09
17.6
19.7
4.83
4.80
e12/l
0.47
170
1715
6
57
1.05
0.08
1.2
1.1
—
—
—
0
0
5
62
0.80
0.08
1.8
5.4
—
—
—
0
0
178
1794
0.91
0.08
17.7
19.8
261.77
259.21
e9/l
0.21
170
1719
178
1794
0.91
0.08
17.7
19.8
7.02
6.61
e9/l
1.38
170
1712
5
65
0.76
0.08
1.4
1.2
—
—
—
0
0
8
74
1.08
0.07
1.4
3.2
58.09
52.47
%
—
8
74
8
76
1.05
0.07
2.0
1.6
253.13
333.23
mu/l
—
8
76
75
769
0.96
0.07
6.4
12.3
—
—
—
0
0
93
949
0.96
0.07
6.4
12.1
49.14
49.38
%
0.07
93
930
8
93
0.85
0.07
1.4
2.0
—
—
—
0
0
9
104
0.86
0.06
10.8
21.9
0.69
1.22
%
—
9
104
12
131
0.91
0.06
2.5
2.1
126.80
149.07
u/ml
—
5
58
42
406
1.04
0.05
10.1
11.6
1.60
1.12
mmol/l
0.73
32
342
101
995
1.03
0.05
7.5
12.2
2.43
2.30
e9/l
0.47
86
826
13
120
1.09
0.05
1.1
1.4
3.56
3.67
mmol/l
—
8
79
42
407
1.04
0.05
10.1
11.8
7.37
7.37
ph
0.35
32
274
17
180
0.94
0.04
1.3
1.2
7.71
7.56
u/ml
0.01
11
142
33
319
1.04
0.04
2.2
1.7
98.89
101.02
pmol/l
0.09
15
158
62
631
0.97
0.03
4.9
9.7
—
—
—
0
0
14
132
1.07
0.02
8.6
21.5
7.40
7.39
ph
—
7
39
30
309
0.97
0.02
1.5
1.7
—
—
—
0
0
39
399
0.97
0.02
10.5
11.3
5.48
5.25
kpa
0.28
39
388
98
971
1.02
0.02
7.6
12.1
0.04
0.04
e9/l
0.38
81
782
92
928
0.98
0.01
9.0
14.1
0.00
0.00
e9/l
0.80
73
691
98
972
1.02
0.01
7.4
12.1
0.65
0.58
e9/l
1.03
81
783
11
116
0.95
0.01
1.2
1.2
—
—
—
0
0
15
144
1.05
0.00
1.6
2.3
—
—
—
0
0
17
176
0.96
0.00
1.3
1.3
1.96
1.47
u/ml
—
10
135
27
266
1.02
0.00
2.5
2.7
15.00
29.71
ng/l
0.78
13
149
29
286
1.02
0.00
1.4
1.3
—
—
—
0
0
47
469
1.00
0.00
4.6
4.6
8.70
9.14
mmol/l
0.19
41
449
157
1573
0.99
0.00
11.7
13.4
28.53
25.25
mg/l
0.53
115
1088
103
1035
0.99
0.00
8.7
14.5
3.93
3.42
e9/l
1.31
84
838
21
205
1.03
0.00
3.0
4.7
1.41
75.50
mg/mmol
0.54
16
159
24
235
1.02
0.00
1.6
2.1
—
—
—
0
0
0
6
0.00
0.00
0.0
2.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
144.50
—
0
6
0
6
0.00
0.00
0.0
3.7
—
139.67
—
0
6
0
6
0.00
0.00
0.0
1.2
—
26.33
—
0
6
0
6
0.00
0.00
0.0
1.2
—
77.50
—
0
6
0
7
0.00
-0.00
0.0
2.1
—
4.10
—
0
7
5
49
1.02
-0.00
4.8
4.0
2.26
20.47
u/ml
—
5
49
5
51
0.98
-0.00
1.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
3.5
—
20.00
—
0
8
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
5
55
0.91
-0.00
12.6
3.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
473.60
—
0
5
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
13.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.6
—
30.54
—
0
5
0
9
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.8
—
—
—
0
0
0
9
0.00
-0.00
0.0
2.3
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded (different definition than used in FinnGen).

Relationships between endpoints

↥

Index endpoint: Q17_ECTOPIC_TESTIS – Ectopic testis

GWS hits: -

This endpoint is excluded (different definition than used in FinnGen).